Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising
effects on prolonging progression-free survival (PFS) for advanced chondrosarcoma after
failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which
specifically inhibits VEGFR-2. This study summarizes the experience of two Peking University
affiliated hospitals in off-label use of apatinib in the treatment of extensively pre-treated
chondrosarcoma.